2.1 Data Source
This study was designed as a retrospective study, the interventions of
interest was voriconazole. All records in the FAERS database from
January 2004 to March 2022 were included in this study [8]. We used
both generic names and brand names to identify voriconazole and control
drugs (see details in Supplementary Materials Table S1 ).
A deduplication procedure was performed according to the FDA’s
recommendations to select the latest FDA_DT with the same CASEID and
select the higher PRIMARYID when CASEID and FDA_DT are both the same
adverse events (AE) were included when they were considered the
“Primary Suspect (PS) drug (drugs which directly suspected of causing
the adverse events)”.